Table 3 Clinical adverse events at 6‐month follow‐up in patients treated with SES for protected and unprotected LMCA disease.
| Adverse events | Protected LMCA (n = 118) | Unprotected LMCA (n = 82) | p Value |
|---|---|---|---|
| All‐cause death (%) | 3.4 | 7.4 | 0.2 |
| Myocardial infarction (%) | 0.9 | 0 | 1.0 |
| TVR (%) | 8.8 | 6.7 | 0.6 |
| All revascularisations (%) | 12.2 | 10.7 | 0.8 |
| PCI (%) | 11.1 | 9.0 | 0.6 |
| CABG (%) | 0.9 | 1.3 | 0.8 |
| Stroke (%) | 1.8 | 0 | 0.8 |
| Death/MI/stroke (%) | 5.9 | 7.4 | 0.7 |
| Death/MI/TVR (%) | 13.1 | 14.1 | 0.8 |
CABG, coronary artery bypass graft; LMCA, left main coronary artery; MI, myocardial infarction; PCI, percutaneous coronary intervention; SES, sirolimus‐eluting stent; TVR, target vessel revascularisation.